Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 4/20 | 0.33 |
| ▸ | CTSA | P10619 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487462 | 0.84 | PPARA (0.41) | PPARALMNAGAATSHRKMT2A | |
| SCHEMBL4836817 | 0.82 | PPARA (0.41) | PPARALMNAGAATSHRKMT2A | |
| SCHEMBL4827340 | 0.81 | PPARA (0.33) | PPARALMNAGAATSHRKMT2A | |
| SCHEMBL4827344 | 0.78 | LMNA (0.41) | PPARALMNAGAATSHRKMT2A | |
| SCHEMBL5725307 | 0.72 | PPARA (0.58) | PPARALMNAGAATSHRKMT2A | |
| SCHEMBL4829980 | 0.71 | S1PR1 (0.33) | PPARALMNAGAATSHRKMT2A | |
| SCHEMBL4829988 | 0.71 | HPGD (0.41) | PPARALMNAGAATSHRKMT2A | |
| SCHEMBL4834937 | 0.70 | HPGD (0.44) | PPARALMNAGAATSHRKMT2A | |
| SCHEMBL14106685 | 0.70 | HPGD (0.44) | PPARALMNAGAATSHRKMT2A | |
| SCHEMBL4837273 | 0.70 | HPGD (0.40) | PPARALMNAGAATSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884812-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-26 | — | — | US | disclosed |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | PNLIP, LIPC, APOB | PPARA 383/4885LMNA 1312/4885GAA 565/4885 |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | PNLIP, LIPC, APOB | PPARA 365/4885LMNA 1215/4885GAA 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.